Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Placebo

First Posted Date: 2017-09-12

Last Posted Date: 2025-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 67

Registration Number: NCT03280030

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Other: Placebo
Biological: LNA043

First Posted Date: 2017-09-07

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT03275064

Locations: 🇩🇰
Novartis Investigative Site, Hvidovre, Denmark

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Phase 2

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: crizanlizumab

First Posted Date: 2017-08-29

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT03264989

Locations: 🇺🇸
Childrens Healthcare of Atlanta ., Atlanta, Georgia, United States
🇺🇸
University of Maryland Medical Ctr, Baltimore, Maryland, United States
🇺🇸
East Carolina University East Carolina University, Greenville, North Carolina, United States

and more 8 locations

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: AIN457 150 mg
Biological: Placebo
Biological: GP2017 (adalimumab biosimilar)

First Posted Date: 2017-08-23

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 859

Registration Number: NCT03259074

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2017-08-22

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT03257358

Locations: 🇺🇸
Novartis Investigative Site, Neenah, Wisconsin, United States

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol maleate
Drug: Indacaterol acetate
Drug: Placebo

First Posted Date: 2017-08-22

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03257995

Locations: 🇺🇸
Novartis Investigative Site, El Paso, Texas, United States

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Matching placebo of ofatumumab
Drug: Ofatumumab

First Posted Date: 2017-08-15

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT03249714

Locations: 🇷🇺
Novartis Investigative Site, Novosibirsk, Russian Federation

Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

Phase 2

Completed

Conditions: Cocaine-related Disorder

Interventions: Drug: Placebo
Drug: AFQ056

First Posted Date: 2017-08-08

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03242928

Locations: 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2

Withdrawn

Conditions: Carcinoma
Non-Small-Cell Lung Cancer

Interventions: Drug: INC280

First Posted Date: 2017-08-07

Last Posted Date: 2018-07-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03240393

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: QAW039

First Posted Date: 2017-07-21

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 704

Registration Number: NCT03226392

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy